Pfizer Inc. and Valneva SE announced in a release, the completion of three doses of Lyme disease vaccine VLA15 among Phase 3 trial participants.
The trial, “Vaccine Against Lyme for Outdoor Recreationists” (VALOR), “is a multicenter, placebo-controlled, randomized, observer-blinded trial conducted at sites in areas where Lyme disease is highly endemic across the U.S., Canada, and Europe.”
According to the release, “Trial participants aged 5 years and older were randomized 1:1 into two trial groups and receive four doses of either VLA15 or a saline placebo – one dose each at months 0, 2, 5-9 and a booster one year after the third dose, shortly before the peak of the next Lyme disease season.”
